GRF Stock Overview
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives.
Price History & Performance
|Historical stock prices|
|Current Share Price||€9.08|
|52 Week High||€22.10|
|52 Week Low||€9.45|
|1 Month Change||-24.97%|
|3 Month Change||-49.64%|
|1 Year Change||-58.19%|
|3 Year Change||-65.73%|
|5 Year Change||-61.71%|
|Change since IPO||245.98%|
Recent News & Updates
Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|GRF||ES Biotechs||ES Market|
Return vs Industry: GRF underperformed the Spanish Biotechs industry which returned -24.1% over the past year.
Return vs Market: GRF underperformed the Spanish Market which returned -14.3% over the past year.
|GRF Average Weekly Movement||6.5%|
|Biotechs Industry Average Movement||7.6%|
|Market Average Movement||3.5%|
|10% most volatile stocks in ES Market||6.4%|
|10% least volatile stocks in ES Market||0.5%|
Stable Share Price: GRF is more volatile than 90% of Spanish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: GRF's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
|1940||27,584||Raimon Grifols Roura||https://www.grifols.com|
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.
Grifols Fundamentals Summary
|GRF fundamental statistics|
Is GRF overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GRF income statement (TTM)|
|Cost of Revenue||€3.29b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.088|
|Net Profit Margin||1.15%|
How did GRF perform over the long term?See historical performance and comparison
4.0%Current Dividend Yield
Is GRF undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GRF?
Other financial metrics that can be useful for relative valuation.
|What is GRF's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does GRF's PE Ratio compare to its peers?
|GRF PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
PHM Pharma Mar
ROVI Laboratorios Farmaceuticos Rovi
FAE Faes Farma
Price-To-Earnings vs Peers: GRF is expensive based on its Price-To-Earnings Ratio (103.4x) compared to the peer average (23.7x).
Price to Earnings Ratio vs Industry
How does GRF's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings vs Industry: GRF is expensive based on its Price-To-Earnings Ratio (103.4x) compared to the European Biotechs industry average (32.1x)
Price to Earnings Ratio vs Fair Ratio
What is GRF's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||103.4x|
|Fair PE Ratio||31.7x|
Price-To-Earnings vs Fair Ratio: GRF is expensive based on its Price-To-Earnings Ratio (103.4x) compared to the estimated Fair Price-To-Earnings Ratio (31.6x).
Share Price vs Fair Value
What is the Fair Price of GRF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GRF (€9.08) is trading below our estimate of fair value (€18.86)
Significantly Below Fair Value: GRF is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Grifols forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GRF's forecast earnings growth (34.2% per year) is above the savings rate (0.9%).
Earnings vs Market: GRF's earnings (34.2% per year) are forecast to grow faster than the Spanish market (11.6% per year).
High Growth Earnings: GRF's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GRF's revenue (10.1% per year) is forecast to grow faster than the Spanish market (3.7% per year).
High Growth Revenue: GRF's revenue (10.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GRF's Return on Equity is forecast to be low in 3 years time (13.4%).
Discover growth companies
How has Grifols performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GRF has high quality earnings.
Growing Profit Margin: GRF's current net profit margins (1.1%) are lower than last year (12.8%).
Past Earnings Growth Analysis
Earnings Trend: GRF's earnings have declined by 14.9% per year over the past 5 years.
Accelerating Growth: GRF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GRF had negative earnings growth (-91.1%) over the past year, making it difficult to compare to the Biotechs industry average (-15.8%).
Return on Equity
High ROE: GRF's Return on Equity (1.7%) is considered low.
Discover strong past performing companies
How is Grifols's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: GRF's short term assets (€4.4B) exceed its short term liabilities (€1.7B).
Long Term Liabilities: GRF's short term assets (€4.4B) do not cover its long term liabilities (€11.0B).
Debt to Equity History and Analysis
Debt Level: GRF's net debt to equity ratio (94.3%) is considered high.
Reducing Debt: GRF's debt to equity ratio has reduced from 171.2% to 100.8% over the past 5 years.
Debt Coverage: GRF's debt is not well covered by operating cash flow (3.4%).
Interest Coverage: GRF's interest payments on its debt are not well covered by EBIT (1.4x coverage).
Discover healthy companies
What is Grifols's current dividend yield, its reliability and sustainability?
Dividend Score 1/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|Grifols Dividend Yield vs Market|
|Market Bottom 25% (ES)||2.3%|
|Market Top 25% (ES)||6.1%|
|Industry Average (Biotechs)||2.1%|
|Analyst forecast in 3 Years (Grifols)||2.5%|
Notable Dividend: GRF's dividend (3.96%) is higher than the bottom 25% of dividend payers in the Spanish market (2.31%).
High Dividend: GRF's dividend (3.96%) is low compared to the top 25% of dividend payers in the Spanish market (6.08%).
Stability and Growth of Payments
Stable Dividend: GRF has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: GRF's dividend payments have increased, but the company has only paid a dividend for 9 years.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (411.4%), GRF's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: GRF is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Raimon Grifols Roura (58 yo)
Mr. Raimon Grifols Roura has been the Co-Chief Executive Officer of Grifols, S.A. since January 1, 2017 and served as its Co-Chairman. Mr. Roura was a Patner at Osborne Clarke Spain. Mr. Roura serves as th...
CEO Compensation Analysis
|Raimon Grifols Roura's Compensation vs Grifols Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||€895k||€895k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||€1m||€895k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||€1m||n/a|
Compensation vs Market: Raimon's total compensation ($USD863.07K) is below average for companies of similar size in the Spanish market ($USD2.52M).
Compensation vs Earnings: Raimon's compensation has been consistent with company performance over the past year.
Experienced Management: GRF's management team is seasoned and experienced (15.7 years average tenure).
Experienced Board: GRF's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Grifols, S.A.'s employee growth, exchange listings and data sources
- Name: Grifols, S.A.
- Ticker: GRF
- Exchange: BME
- Founded: 1940
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €5.850b
- Shares outstanding: 678.91m
- Website: https://www.grifols.com
Number of Employees
- Grifols, S.A.
- Avinguda de la Generalitat, 152
- Parc empresarial Can Sant Joan
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GRF||BME (Bolsas y Mercados Espanoles)||Yes||Class A Shares||ES||EUR||May 2006|
|OZTA||DB (Deutsche Boerse AG)||Yes||Class A Shares||DE||EUR||May 2006|
|0RDU||LSE (London Stock Exchange)||Yes||Class A Shares||GB||EUR||May 2006|
|GIFL.F||OTCPK (Pink Sheets LLC)||Yes||Class A Shares||US||USD||May 2006|
|GRFE||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Class A Shares||GB||EUR||May 2006|
|GRF||WBAG (Wiener Boerse AG)||Yes||Class A Shares||AT||EUR||May 2006|
|OZTA||ETLX (Eurotlx)||Yes||Class A Shares||IT||EUR||May 2006|
|GIKL.Y||OTCPK (Pink Sheets LLC)||SPON ADR EA REPR 1/2 ORD SHS EUR0.50||US||USD||Jul 2009|
|G0F||DB (Deutsche Boerse AG)||SPON ADR EA REPR 1/2 ORD SHS EUR0.50||DE||EUR||Jul 2009|
|GRFS||NasdaqGS (Nasdaq Global Select)||SPON ADR EA REPR 1 ORD EUR0.10||US||USD||Jun 2011|
|GRF.P||BME (Bolsas y Mercados Espanoles)||Class B Non-Voting Shares||ES||EUR||Jun 2011|
|0RDV||LSE (London Stock Exchange)||Class B Non-Voting Shares||GB||EUR||Jun 2011|
|G0FB||DB (Deutsche Boerse AG)||SPON ADR EA REPR 1 ORD EUR0.10||DE||EUR||Jun 2011|
|GRFPE||BATS-CHIXE (BATS 'Chi-X Europe')||Class B Non-Voting Shares||GB||EUR||Jun 2011|
|GIFO.F||OTCPK (Pink Sheets LLC)||Class B Non-Voting Shares||US||USD||Jun 2011|
|GRFP N||BMV (Bolsa Mexicana de Valores)||Class B Non-Voting Shares||MX||MXN||Jun 2011|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.